Study of Elacytarabine Versus Investigator's Choice in Patients With Late Stage Acute Myeloid Leukaemia (AML)
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- David Rizzieri, MD
Duke University Medical Center, Durham, NC, USA
Principal InvestigatorKOL profile → - Francis J Giles, MD, PhD
Cancer Therapy & Reseach Center at the University of Texas Health Science Center San Antonio, TX, USA
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
73 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Royal North Shore Hopsital
Sydney, New South Wales, Australia
- Alfred Hospital
Melbourne, Victoria, Australia
- Box Hill Hospital
Melbourne, Victoria, Australia
- Sir Charles Gairdner Hospital
Perth, Western Australia, Australia
- Algemeen Ziekenhuis Sint-Jan
Bruges, Belgium
- Institut Jules Bordet
Brussels, Belgium
- Uz Brussel
Brussels, Belgium
- University Hospital Antwerp
Edegem, Belgium
- Chu Liège
Liège, Belgium
- Ucl Mont-Godinne
Yvoir, Belgium
- Princess Margaret Hospital
Toronto, Ontario, Canada
- Chu Limoges - Hôpital Dupuytren
Limoges, France
- Hopital Edouard Herriot
Lyon, France
- Institut J. Paoli and I. Calmettes
Marseille, France
- Centre Antoine Lacassagne
Nice, France
- Hopital Saint Antoine
Paris, France
- Chu de Bordeaux - Hopital Haut-Leveque
Pessac, France
- Chu de Toulouse - Hôpital Purpan
Toulouse, France
- Charité-Campus B. Franklin Med. Klinik Haematology
Berlin, Germany
- Evangelische Kliniken Johanniter- Und Waldkrankenhaus Bonn Gmbh
Bonn, Germany
- Heinrich-Heine Universität Düsseldorf, Klinik Für Hämatologie/onkolog. Und Klin. Immunologie
Düsseldorf, Germany
- Iii. Medizinische Klinik Und Poliklinik;hämatologie, Onkologie Und Pneumologie
Mainz, Germany
- Universitätsklinikum Münster, Medisinische Klinik & Poliklinik A
Münster, Germany
- Universitätsklinikum Rostock
Rostock, Germany
- Robert-Bosch-Krankenhaus, Abt.Hämatologie,onkologie U.Palliativmedizin
Stuttgart, Germany
- Universitätsklinikum Ulm, Klinik Für Innere Medizin Iii, Comprehensive Cancer Center Ulm (cccu)
Ulm, Germany
- St James'S Hospital Dublin
Dublin, Ireland
- University Hospital Galway
Galway, Ireland
- A.O.U Careggi
Florence, Italy
- A.O San Martino
Genova, Italy
- Fondazione San Raffaele del Monte Tabor
Milan, Italy
- A.O. Cardarelli
Naples, Italy
- Hospital S. Maria Delle Croci
Ravenna, Italy
- Fondazion Policlin T Vergata
Roma, Italy
- Haukeland Universitetssykehus
Bergen, Norway
- Oslo University Hospital
Oslo, Norway
- St Olavs Hospital
Trondheim, Norway
- Samodzielny Publiczny Szpital Kliniczny Nr 1 We Wroclawiu
Wroclaw, Poland
- Fundeni Clinical Institute "stefan Berceanu" Center for Hematology and Bone Marrow Transplant
Bucharest, Romania
- Oncology Institute ,,ion Chiricuta" Cluj Napoca , Hematology Dept.
Cluj-Napoca, Romania
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Jun 2010
- Primary completion
- 28 Feb 2013
- Completion
- 30 Jun 2013
- Last update posted
- 27 Sept 2013
- Registered enrollment
- 381
- Registry id
- NCT01147939
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.